The effectiveness of COVID-19 vaccination in preventing new severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infections in the general community is still unclear. Here, …

We report that in a cohort of 45,965 adults, who were receiving either the ChAdOx1 or the
BNT162b2 SARS-CoV-2 vaccines, in those who had no prior infection with SARS-CoV-2, …

Background Decisions about the continued need for control measures to contain the spread
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rely on accurate and up-…

Tracking Emergence of Alpha Variant In this report, investigators in the United Kingdom
looked for clues regarding the rapid emergence and dissemination of the SARS-CoV-2 …

Background: Information on SARS-CoV-2 in representative community surveillance is limited,
particularly cycle threshold (Ct) values (a proxy for viral load). Methods: We included all …

Background A new variant of SARS-CoV-2, B.1.1.7/VOC202012/01, was identified in the UK
in December-2020. Direct estimates of its potential to enhance transmission are limited. …

Objectives To assess the effectiveness of COVID-19 vaccination in preventing SARS-CoV-2
infection in the community. Design Prospective cohort study. Setting The UK population-…

Real-world data on antibody response post-vaccination in the general population are limited.
45,965 adults in the UK’s national COVID-19 Infection Survey receiving Pfizer-BioNTech or …

Background Information on COVID-19 in representative community surveillance is limited,
particularly regarding cycle threshold (Ct) values (a proxy for SARS-CoV-2 viral load) and …

Computational simulations of layered double hydroxides (LDHs), based on relatively simple
models and simulation procedures (classically based force‐field calculations), are shown to …